780 related articles for article (PubMed ID: 25954110)
21. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
22. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J
Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
25. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
[TBL] [Abstract][Full Text] [Related]
26. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
27. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
[TBL] [Abstract][Full Text] [Related]
28. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
[TBL] [Abstract][Full Text] [Related]
29. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
31. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
32. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
[TBL] [Abstract][Full Text] [Related]
33. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
34. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M
Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151
[TBL] [Abstract][Full Text] [Related]
38. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
[TBL] [Abstract][Full Text] [Related]
39. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS; Love S; Segelov E; Johnstone E; Falcon B; Hewett P; Weaver A; Church D; Scudder C; Pearson S; Julier P; Pezzella F; Tomlinson I; Domingo E; Kerr DJ
Lancet Oncol; 2016 Nov; 17(11):1543-1557. PubMed ID: 27660192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]